March 2016. Volume 12. Number 1

There is no evidence that azithromycin reduces the severity of recurrent wheezing

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Bacharier LB, Guilbert TW, Mauger DT, Boehmer S, Beigelman A, Fitzpatrick AM, et al. Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial. JAMA. 2015;314:2034-44.

Reviewers: Ortega Páez E1, Ruiz-Canela Cáceres J2.
1CS Maracena. Distrito Granada-Metropolitano. Granada. España.
2CS Virgen de África. Sevilla. España.
Correspondence: Eduardo Ortega Páez. Email: edortegap@gmail.com
Reception date: 02/03/2016
Acceptance date: 04/03/2016
Publication date: 09/03/2016

Abstract

Authors’ conclusions: among children with a history of severe recurrent episodes of wheezing, early administered azithromycin reduces the likelihood of severe recurrent wheezing. More information about the development of resistance due to this strategy is needed.

Reviewers’ commentary: because of its methodological weaknesses, the results of this trial, on the reduction of severe recurrent wheezing after administration of AZT, should be considered with caution and inconclusive. It is to conduct further studies to define precisely which patients would benefit from the use of AZT, for the prevention of recurrent wheezing, minimizing the side effects of it.

How to cite this article

Ortega Páez E, Ruiz-Canela Cáceres J. No hay pruebas de que la azitromicina reduzca la gravedad de las sibilancias recurrentes. Evid Pediatr. 2016;12:18.

AVC | Critically appraised articles

Bacharier LB, Guilbert TW, Mauger DT, Boehmer S, Beigelman A, Fitzpatrick AM, et al. Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial. JAMA. 2015;314:2034-44.

Reviewers: Ortega Páez E1, Ruiz-Canela Cáceres J2.
1CS Maracena. Distrito Granada-Metropolitano. Granada. España.
2CS Virgen de África. Sevilla. España.
Correspondence: Eduardo Ortega Páez. Email: edortegap@gmail.com
Reception date: 02/03/2016
Acceptance date: 04/03/2016
Publication date: 09/03/2016

How to cite this article

Ortega Páez E, Ruiz-Canela Cáceres J. No hay pruebas de que la azitromicina reduzca la gravedad de las sibilancias recurrentes. Evid Pediatr. 2016;12:18.

References

  1. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ; et al. Asthma and wheezing in the first 6 years of life. N Engl J Med. 1995;332:133-8.
  2. Kloepfer KM, Lee WM, Pappas TE, Kang TJ, Vrtis RF, Evans MD, et al. Detection of pathogenic bacteria during rhinovirus infection is associated with increased respiratory symptoms and asthma exacerbations. J Allergy Clin Immunol. 2014;133:1301-7.e1-3.
  3. Gómez-Acebo I, Dierssen-Sotos T, Llorca J. Número necesario de tratamientos: interpretación y estimación en análisis multivariables y con datos censurados. Med Clin (Barc). 2014;142:451-6.
  4. Martínez-González MA, Alonso A, López Fidalgoa J. ¿Qué es una hazard ratio? Nociones de análisis de supervivencia. Med Clin (Barc). 2008;131:65-72.
  5. Tokholm J, Chawes BL, Vissing NH, Bjarnadóttir E, Pedersen TM, Vinding RK, et al. Azithromycin for episodes with asthma-like symptoms in young children aged 1-3 years: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2016;4:19-26.
  6. Kozyrskyj AL, Dahl ME, Ungar WJ, Becker AB, Law BJ. Antibiotic treatment of wheezing in children with asthma: what is the practice? Pediatrics. 2006;117:e1104-e10.
  7. Costelloe C, Metcalfe C,Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ. 2010;340:c2096.

Related Articles

ED | Sibilancias recurrentes y azitromicina. Sin pruebas concluyentes para su empleo como recurso terapéutico

Praena Crespo M. Sibilancias recurrentes y azitromicina. Sin pruebas concluyentes para su empleo como recurso terapéutico. Evid Pediatr. 2016;12:2.
09/03/2016

Linked Comment